Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03860207
What this trial is testing

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Who this might be right for
NeuroblastomaOsteosarcomaOther Solid Tumor Cancers
Y-mAbs Therapeutics 12
Early research (Phase 1)Ended earlyNCT04156100
What this trial is testing

A Study in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Agenus Inc. 19
Testing effectiveness (Phase 2)Ended earlyNCT03440437
What this trial is testing

FS118 in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and Neck
invoX Pharma Limited 80
Testing effectiveness (Phase 2)Ended earlyNCT00522457
What this trial is testing

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Neovii Biotech 19
Early research (Phase 1)Looking for participantsNCT07606612
What this trial is testing

SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 31
Not applicableAvailableNCT05119257
What this trial is testing

(Bispecific) Antibodies in Cancer Patients

Who this might be right for
Cancer
University Hospital Tuebingen
Not applicableLooking for participantsNCT06846905
What this trial is testing

Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Who this might be right for
Multiple Myeloma in Relapse
University Hospital, Toulouse 40
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06432296
What this trial is testing

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Who this might be right for
Malignant Ascites
Wuhan YZY Biopharma Co., Ltd. 312
Testing effectiveness (Phase 2)Looking for participantsNCT06959550
What this trial is testing

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
M.D. Anderson Cancer Center 90
Testing effectiveness (Phase 2)UnknownNCT03797391
What this trial is testing

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Who this might be right for
NeoplasmsNeoplasm MetastasisNon-Small-Cell Lung Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd. 186
Testing effectiveness (Phase 2)Ended earlyNCT05660967
What this trial is testing

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 111
Testing effectiveness (Phase 2)Ended earlyNCT04618393
What this trial is testing

EMB-02 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd. 47
Testing effectiveness (Phase 2)WithdrawnNCT03509298
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Who this might be right for
Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07830485
What this trial is testing

CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 24
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Testing effectiveness (Phase 2)Looking for participantsNCT06976476
What this trial is testing

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Who this might be right for
Multiple MyelomaHypogammaglobulinemiaHypogammaglobulinemia, Acquired
Memorial Sloan Kettering Cancer Center 100
Early research (Phase 1)Study completedNCT00938626
What this trial is testing

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT01741792
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Amgen Research (Munich) GmbH 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07687004
What this trial is testing

Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 50
Next Page